Patients with COVID-19 and a history of CV disease in particular, as well as those with increased levels of CV biomarkers—most notably high-sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP)—face an increased risk of morbidity and mortality. Here, TNNI3 is linked to COVID-19.